AAV-directed persistent expression of an anti-nicotine antibody gene for smoking cessation
US10093947B2 · kind B2 · utility
0Cited by
0References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 25, 2013 |
| Grant date | Oct 9, 2018 |
| Priority date | — |
| Expiry date | Feb 25, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2750/14143
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention is directed to an adeno-associated virus (AAV) vector which comprises a nucleic acid sequence encoding an antibody or antigen binding fragment that binds to nicotine or a nicotine analog. The invention also is directed to a composition comprising the AAV vector and methods of using the AAV vector to induce an immune response against nicotine in a mammal.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.